Barcelona spin-off behind HER2DX, a genomic test that guides treatment decisions in HER2 positive breast cancer. Hologic agreed to acquire the company in October 2026.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
No Spam. Unsubscribe anytime.